ClearPoint Neuro, Inc. (CLPT)
After hours:
| Previous Close | 12.58 |
| Open | 12.78 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 12.27 - 13.14 |
| 52 Week Range | 4.05 - 14.13 |
| Volume | |
| Avg. Volume | 203,571 |
| Market Cap | 359.848M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.70 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
GlobeNewswireClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 third quarter on Thursday, November 7th at 4:30 p.m
- GlobeNewswire
ClearPoint Neuro Announces Early Repayment of $10 Million Note
SOLANA BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that on August 23, 2024, it provided for the full early repayment of the principal amount and interest on a $10 million convertible note held by PTC Therapeutics Inc., which would have matured in January 2025 according to its terms. The convertible note was issued
